In the SIBAMATE study, more than 60% of patients lost at least 5% of body weight after 3 months of using ...

The 2018 Lancet Commission,1 After asthma: redefining airways diseases, made clear recommendations to improve outcomes for ...

VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe ...

Indianapolis: Eli Lilly and Company has announced that the European Commission (EC) has granted marketing authorization for ...

VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3 ...

Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 1:10 PM EDTCompany ParticipantsTom Cavanaugh - ...

By seeing yourself with grace, you create an internal safe space where you can grow. You can love your shadow and feel unconditional love, When you have your own back, you’ll feel braver to take the ...

Aficamten is also currently being evaluated in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM; CEDAR-HCM, a clinical trial of aficamten in a pediatric ...

Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline Only therapy with evidence to ...

Background Hospitalisation with acute heart failure (AHF) carries a high risk of death, and those surviving to discharge ...

Optical Surfaces Ltd has introduced a novel approach to large-diameter optical systems with its pre-aligned beam collimator ...